Aims: To investigate the efficacy and safety of alirocumab in participants with type 2 (T2D) or type 1 diabetes (T1D) treated with insulin who have elevated LDL cholesterol levels despite maximally tolerated statin therapy.
| INTRODUCTION
Dyslipidaemia is a major risk factor for macrovascular complications in both type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D). 1, 2 In T2D, the development of dyslipidaemia, typically characterized by elevated levels of non-HDL cholesterol and triglycerides (TGs) and reduced levels of HDL cholesterol, is associated with insulin resistance in most cases. 3, 4 By contrast, well-controlled individuals with T1D can have a normal lipid profile, with lower TG and LDL cholesterol levels and HDL cholesterol levels in the upper normal range or even slightly elevated 2, 5 ; however, in the presence of poor glycaemic control, the profile of dyslipidaemia in individuals with T1D may resemble that observed with T2D. 4 Standard-of-care LDL cholesterol-lowering by statins, and in combination with ezetimibe, has been shown to lead to significant reductions in cardiovascular events in individuals with diabetes. [6] [7] [8] Current guidelines generally recommend targeting an LDL cholesterol goal of <1.8 mmol/L (<70 mg/dL), or even <1.3 mmol/L (<50 mg/dL), and/or a reduction of ≥50% from baseline in patients with T2D or T1D considered to be at high or very high cardiovascular risk. 5, 9, 10 Despite such strong recommendations, a significant proportion of individuals with diabetes do not reach target LDL cholesterol levels in real-life studies, [11] [12] [13] and are therefore exposed to significant residual risk of cardiovascular events.
Alirocumab, a monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), has been shown to have similar efficacy and safety in individuals with and without diabetes in post hoc analyses. [14] [15] [16] Some theoretical considerations have been raised with regard to the use of PCSK9 inhibitors in individuals with diabetes. [17] [18] [19] Specifically, these include the safety of the concomitant administration of 2 injectable agents (alirocumab, a monoclonal antibody, and insulin, a biological agent). The potential for the effects of alirocumab on glycaemic control and change in antidiabetic medication use, as well as immunogenicity in individuals with T2D and T1D, also warrants further investigation.
The phase IIIb ODYSSEY DM-INSULIN study therefore sought to characterize the efficacy and safety of alirocumab in insulin-treated individuals with T1D or T2D at high cardiovascular risk not reaching LDL cholesterol goals, despite maximum tolerated statin therapy, with or without other lipid-lowering therapies (LLTs).
| MATERIALS AND METHODS

| Study design
ODYSSEY DM-INSULIN was a phase IIIb, randomized, double-blind, placebo-controlled, parallel-group, multicentre trial, conducted at 103 sites in 10 countries (Austria, Belgium, France, Germany, Italy, the Netherlands, Spain, Switzerland, the UK, and the USA) and designed to evaluate the efficacy and safety of alirocumab in insulintreated people with hypercholesterolaemia and at high cardiovascular risk (a complete list of study sites and investigators is available in the Supporting Information, Text S1). Trial design and rationale have been published previously. 20 The study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guidelines for Good Clinical Practice. The institutional review board or independent ethics committee at each study centre approved the study protocol, and written informed consent was obtained from each participant. The trial was registered with clinicaltrials.gov (Clinical trial reg. no. NCT02585778).
| Study population
The study population comprised people with insulin-treated T2D or 
| Study procedures
Briefly, the study consisted of a screening period of up to 3 weeks and a double-blind treatment period of 24 weeks, followed by a safety observation period of 8 weeks. Participants were on a stable diet for glucose and lipid management, and received treatment for diabetes in accordance with local/regional standards of care.
Eligible participants were randomized to alirocumab or placebo 
| Endpoints and assessments
The primary efficacy endpoint was the percent change in calculated LDL cholesterol from baseline to week 24. Primary safety endpoints
were assessed (up to week 32) through treatment-emergent adverse event (TEAE) reports, laboratory data, product complaints, and vital signs (including height, weight, blood pressure and heart rate). Table S1 and Text S3.
| Statistical analysis
The primary efficacy endpoint was evaluated in the intention-to-treat population; missing data were accounted for using a mixed effects model with a repeated measures approach, 23, 24 using all available post-baseline data within the analysis windows (weeks [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] 3 | RESULTS
| Participants
In total, 441 participants with T2D and 76 with T1D were randomized 2:1 to receive alirocumab or placebo; of these, 469 (90.7%) completed the study on study treatment ( Figure 1 ).
Baseline characteristics were generally well balanced between the treatment groups for both the T2D and T1D populations ( Table S5 , Supporting Information). In addition, 70.9% of the alirocumab group and 13.8% of the placebo group attained non-HDL cholesterol <2.6 mmol/L (<100 mg/dL; P < .0001 [Table S5 ,
Supporting Information]). Reductions from baseline to week 24 (difference vs placebo) in TG levels (−5.7%) were also observed, although
were not significant (P = .0902 [ Table 2 ]). Reductions (difference vs placebo) in LDL particle number (−40.2%; P < .0001) and LDL particle size (−2.5%; P < .0001) at week 24 were observed, although significance was nominal because of the hierarchical testing procedure used ( 
| Alirocumab efficacy in participants with T1D
For the primary efficacy endpoint in participants with T1D, the LS mean (s.e.) percentage change in LDL cholesterol concentrations from baseline to week 24 was −51.8% (3.7%) for alirocumab and −3.9% Table 2 ]). Alirocumab resulted in an increase in HDL cholesterol (difference vs placebo 3.9%), although this was not significant (P = .3434 [ Table 2] ). In addition, alirocumab resulted in a decrease in TG levels (difference vs placebo −15.5%, nominal P = .056). A reduction in LDL particle number (difference vs placebo) from baseline to week 24 of −40.0% was also observed (nominal P <.0001). Results of other efficacy endpoints were similar to those described for the T2D population above (Tables S5 and S6 , Supporting Information).
| Diabetes-related endpoints
In the T2D population, the mean (standard deviation [s. 
| Safety and tolerability
The proportion of participants with at least 1 TEAE was similar between the alirocumab and placebo treatment groups, both for the overall population combining T2D and T1D (64.5% vs 64.1%
[ Abbreviations: Apo-CIII, apolipoprotein C-III; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; CHD, coronary heart disease; CKD, chronic kidney disease; CV, cardiovascular; eGFR, estimated glomerular filtration rate.
a CHD defined as history of acute myocardial infarction, silent myocardial infarction, unstable angina, coronary revascularization procedure, or clinically significant CHD diagnosed by invasive or non-invasive testing.
b CV risk factors (in addition to diabetes and hypercholesterolaemia) included hypertension, current smoker, age ≥45 years (men) or ≥55 years (women), history of micro-/macroalbuminuria or diabetic retinopathy, family history of premature CHD, low levels of HDL cholesterol, or documented CKD. f Percentage of patients receiving any statin.
g Number of participants not currently taking statin who are statin-intolerant based on medical history, as reported by investigator.
h One participant was not receiving statin therapy at randomization, but not classified as statin-intolerant based on medical history.
i One participant in the alirocumab group and one participant in the placebo group were not receiving insulin at the time of randomization, and they remained without insulin treatment for the duration of the trial.
j Intention-to-treat population. Table S9 , Supporting Information).
There were no reported cases of local injection site reactions meeting the predefined AEs of special interest criteria (ie, those allergic in nature requiring consultation) in either the T2D or T1D population (Table 3 and Table S8 , Supporting Information). Local injection-site reaction TEAEs were reported in 5 participants (1.7%) in the alirocumab group vs 5 participants (3.4%) in the placebo group for the T2D population; the occurrence in the T1D population was 2 participants (3.9%) vs 3 participants (12.0%), respectively. Most of the local injection-site reactions were mild in intensity, with only 2 occurrences
(1 each in the alirocumab and placebo group) of a moderate intensity.
Other predefined AEs of special interest are shown in Table 3 .
For the T2D population, 3.2% of alirocumab and 0% of placebotreated participants had treatment-emergent persistent antidrug antibodies with a low titre; for the T1D population, 2.1% of alirocumaband 0% of placebo-treated participants had treatment-emergent persistent antidrug antibodies with a low titre. The proportion of participants in the alirocumab group at weeks 12 and 24 with neutralizing antidrug antibodies was 2.1% and 0.7% for the T2D population, and 0% and 2% for the T1D population, respectively. No neutralizing antidrug antibodies were observed in the placebo group.
| Treatment acceptability
Participant-reported acceptability of subcutaneous injection of study treatment was high (including high acceptance of treatment-related side effects) and showed no significant difference between treatment arms in perceived efficacy, acceptance of side effects, injection selfefficacy (confidence in self-injection), injection convenience, or overall acceptance for either the T2D or T1D population (Table S10 , Supporting Information).
| DISCUSSION
This was the first trial with a PCSK9 inhibitor that specifically randomized individuals with insulin-treated diabetes. Subanalyses in individuals with diabetes have previously been reported for PCSK9 inhibitors 14, 16, 25 ; however, conclusions of those analyses were limited because of the non-randomized nature of the subgroups that were assessed. In addition, in previous alirocumab ODYSSEY phase III trials, only a minority of participants with diabetes were receiving insulin, and very few had T1D. 20 In the present study, where 40.1% of participants with T2D also had atherosclerotic cardiovascular disease and remaining participants had additional cardiovascular risk factors, the population of this study represents a group with very high risk of future cardiovascular events, 2,26 who had uncontrolled LDL cholesterol despite receiving maximally tolerated statin.
Alirocumab was shown to be superior in reducing LDL cholesterol levels vs placebo in insulin-treated individuals with T2D or T1D at high cardiovascular risk. A moderate reduction in TGs was observed with alirocumab treatment in both the T2D and T1D populations (small reductions also seen in previous trials), 27 suggesting that inhibiting extracellular PCSK9 has a minor impact, if any, in the metabolism of TGs.
As statins have been found to be associated with an increased risk of diabetes, [29] [30] [31] and because of reports linking PCSK9 to glucose homeostasis, [17] [18] [19] 32, 33 there is an interest in the effect of PCSK9 inhibitors on measures of glycaemic control. Consistent with recent pooled analyses of 10 ODYSSEY phase III studies 34 and 14 ODYSSEY phase II and III studies, 15 which showed no effect of alirocumab on glycaemia in people with or without diabetes, in the present trial, changes in HbA1c and FPG levels were minimal in individuals with either T2D or T1D receiving insulin treatment for the 24-week duration of the trial. Importantly, the total daily insulin dose and number of other antihyperglycaemic drugs were also unchanged for the duration of the study, providing further evidence that alirocumab did not affect glycaemic control. A lack of effect on glycaemic control has also been observed with another PCSK9 inhibitor 35 ; however, the effect of PCSK9 inhibitors on glycaemic control in studies of longer duration (>2 years) needs to be studied. Abbreviations: TEAE, treatment-emergent adverse event; SAE, serious adverse event.
a Participants may be counted in more than one category.
A previous study suggested that PCSK9 may have a reduced role in ApoB catabolism in those with poorly controlled T2D (HbA1c >7%); the negative correlation between plasma PCSK9 and the fractional catabolic rate of LDL-ApoB observed in the non-diabetic group (R = −0.61, P = .002) was only observed in the T2D population in those with HbA1c ≤7% (R = −0.70, P = .08). 36 In the present study, subgroup analyses showed an apparent reduction in placebocorrected LDL cholesterol percentage reduction in the T2D population with baseline HbA1c ≥9% vs lower HbA1c baseline values (Table S4 , Supporting Information); however, this was attributable to an LDL cholesterol reduction of 13.2% observed in the placebo group with HbA1c ≥9%, whereas LDL cholesterol reductions were similar across baseline HbA1c levels in the alirocumab group.
In the present study, alirocumab was well tolerated, with similar proportions of participants with at least 1 TEAE in the alirocumab and placebo groups. In previous alirocumab trials, the frequency of injection-site reactions in the overall patient population was generally found to be higher with alirocumab vs placebo or ezetimibe controls. 37 In the present trial, in participants with T2D or T1D, the overall incidence of local injection-site reactions was low relative to previous studies, with no greater incidence in the alirocumab group relative to placebo; these reactions were generally mild in nature.
Previous subgroup analyses have shown that individuals with diabetes tend to have fewer injection-site reactions than those without diabetes. 15, 16 A higher proportion of participants discontinued treatment with alirocumab because of an AE compared with the placebo group; however, no pattern emerged when analysed at the preferredterm level. The incidence of neurocognitive AEs (1.4% of alirocumabtreated participants only in the T2D population) was similar to that shown in results from a pooled analysis of 14 phase II and III trials, which reported an incidence of 0.9% in the alirocumab group of the placebo-controlled pool. 37 The frequencies of treatment-emergent persistent antidrug antibodies and neutralizing antibodies were similar to those reported previously from a pooled analysis of 10 phase III alirocumab trials, which demonstrated LDL cholesterol reductions that were maintained for the duration of the trials, regardless of antidrug antibody status. 22 Uniquely for a PCSK9 inhibitor, we assessed participant acceptance of study drug injections using the validated I-TAQ survey. 21 Results of this survey indicated that participants were confident in their ability to inject themselves, that there were high levels of acceptance for the injectable study drug, and that there was no difference between treatment arms in the perceived frequency of side effects. These results are consistent with an early study investigating patient perspectives of possible injection devices for alirocumab administration. 
